Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome-Reference-Cited by-同舟云学术

Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome

Published:2017-08-03 Issue:5 Volume:130 Page:625-631
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Milani Paolo¹²³^ORCID,Basset Marco¹²,Russo Francesca¹²,Foli Andrea¹²,Merlini Giampaolo¹²^ORCID,Palladini Giovanni¹²^ORCID

Affiliation:

1. Amyloidosis Research and Treatment Center, Foundation Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy; and

2. Department of Molecular Medicine and

3. PhD Program in Experimental Medicine, University of Pavia, Pavia, Italy

Abstract

Key PointsPatients with AL amyloidosis and low dFLC burden (<50 mg/L) have less severe heart involvement and better survival. These patients are evaluable for hematologic response with adapted criteria predicting improvement of overall and renal survival.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/130/5/625/1403712/blood767467.pdf

Reference33 articles.

1. A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis;Diomede;Blood,2014

2. What is new in diagnosis and management of light chain amyloidosis?;Palladini;Blood,2016

3. Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis;Weiss;Blood,2016

4. Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis;Bochtler;Haematologica,2008

5. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine;Palladini;Clin Chem,2009

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long‐term outcomes of renal AL amyloidosis patients undergoing autologous stem cell transplantation: Validating the performance of the renal staging system;American Journal of Hematology;2024-08-29

2. Redefining Cardiac Involvement and Targets of Treatment in Systemic Immunoglobulin AL Amyloidosis;JAMA Cardiology;2024-08-21

3. A bibliometric analysis of light chain amyloidosis from 2005 to 2024: research trends and hot spots;Frontiers in Medicine;2024-07-30

4. Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy;Amyloid;2024-07-02

5. Clinical Use of Biomarkers in Cardiac Amyloidosis;Heart Failure Clinics;2024-07